Esperion Therapeutics, Inc. is a pharmaceutical company that focuses on developing and distributing medicines for patients with highly elevated low-density lipoprotein cholesterol. Their primary medicines are NEXLETOL and NEXLIZET tablets, which treat atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company was established in 2008 and is based in Ann Arbor, Michigan, with licensing agreements with Daiichi Sankyo Europe GmbH and Serometrix.